top of page

Analyzing Nanobiotix's P1 Head & Neck data for the radioenhancer NBTXR3 from #ASTRO2023

CEO Laurent Levy walks us through the data and makes his argument that patients' overall survival seen on NBTXR3 was greater than what would be expected from historical controls.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page